Literature DB >> 1325033

Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21.

P Robberecht1, P Gourlet, P De Neef, M C Woussen-Colle, M C Vandermeers-Piret, A Vandermeers, J Christophe.   

Abstract

In AR 4-2J rat pancreatic acinar cell membranes, receptors for the two pituitary adenylate cyclase-activating peptides (PACAP) PACAP-27 (the short version of PACAP) and PACAP-38 [the long version, with a carboxyl-terminal (residues 28-38) extension] can be subdivided into (a) type A receptors, with high affinity (Kd, 0.3-0.5 nM) for both PACAP-27 and PACAP-38, and (b) type B receptors, with high affinity for PACAP-38 (Kd, 0.3 nM) but low affinity for PACAP-27 (Kd, 20 nM). Determinants of agonist/antagonist activity in 47 PACAP-27 and PACAP-38 analogs (mono- or disubstituted in positions 1, 2, 3, 20, and 21) or amino-terminally shortened were tested by (a) the occupancy of PACAP-A receptors, preferentially labeled with [125I-N-acetyl-His1]PACAP-27, and that of PACAP-A and -B receptors, both labeled with 125I-PACAP-38, and (b) the resulting activation or inhibition of adenylate cyclase. For PACAP-A receptor recognition, deprotonated His1 was a major determinant for PACAP-27 but not PACAP-38; the Kd of 125I-PACAP-27 decreased 2.4-fold at 37 degrees between pH 6.0 and 7.5 and 3.6-fold at 15 degrees, whereas the IC50 of [N-acetyl-His1]PACAP-27 was less affected and that of PACAP(2-27), PACAP(2-38), and PACAP(1-38) was pH independent. In addition, PACAP-A receptors coupled to adenylate cyclase were much more sensitive to PACAP-38 derivatives than to PACAP-27 derivatives; for instance, [D-Phe2]PACAP-38 was a more potent antagonist (Ki, 5 nM) than [D-Phe2]PACAP-27 (Ki, 350 nM), and PACAP(6-38) was a more potent antagonist (Ki, 7 nM) than PACAP(6-27) (Ki, 300 nM). PACAP-B receptors, apart from showing high affinity for PACAP-38, displayed relatively high affinity for amino-terminally shortened PACAP-38 fragments and poor affinity for PACAP-27 and PACAP-27 fragments.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325033

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors:  C S Walker; T Sundrum; D L Hay
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

2.  Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells.

Authors:  N Lu; E DiCicco-Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

3.  A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.

Authors:  Irene Ramos-Álvarez; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Paola Moreno; Terry W Moody; Jerome L Maderdrut; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-02-16       Impact factor: 3.750

4.  Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.

Authors:  J Van Rampelbergh; M G Juarranz; J Perret; A Bondue; R M Solano; C Delporte; P De Neef; P Robberecht; M Waelbroeck
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

5.  Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells.

Authors:  D Reglodi; R Borzsei; T Bagoly; A Boronkai; B Racz; A Tamas; P Kiss; G Horvath; R Brubel; J Nemeth; G Toth; Z Helyes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

Review 6.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

7.  Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.

Authors:  Christopher R Apostol; Kelsey Bernard; Parthasaradhireddy Tanguturi; Gabriella Molnar; Mitchell J Bartlett; Lajos Szabò; Chenxi Liu; J Bryce Ortiz; Maha Saber; Katherine R Giordano; Tabitha R F Green; James Melvin; Helena W Morrison; Lalitha Madhavan; Rachel K Rowe; John M Streicher; Michael L Heien; Torsten Falk; Robin Polt
Journal:  Front Drug Discov (Lausanne)       Date:  2022-01-14

8.  Agnathan VIP, PACAP and their receptors: ancestral origins of today's highly diversified forms.

Authors:  Stephanie Y L Ng; Billy K C Chow; Jun Kasamatsu; Masanori Kasahara; Leo T O Lee
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.